Research on peptides

Retatrutide research: GIP, GLP-1 and glucagon receptors

Retatrutide research – GIPR GLP-1R and glucagon receptor

Retatrutide research It focuses on the experimental molecule LY3437943, which combines agonist activity on GIP, GLP-1 and glucagon receptors in a single molecular structure. This receptor profile is the reason why retatrutide is being studied as a model of multiple incretin and glucagon signaling.

When interpreting available literature, it is important to distinguish between receptor pharmacology of retatrutide, material used in Eli Lilly clinical studies, and separate research-grade laboratory material. The results of a clinical trial with one investigational formulation cannot be automatically attributed to another commercially available sample.

In short: Retatrutide (LY3437943) is an investigational agonist of three receptor systems – GIPR, GLP-1R and GCGR. The research includes receptor signaling, metabolic mechanisms and extensive clinical development. As of August 2026, Phase 2 data and part of Phase 3 data have been published, with further studies ongoing. Retatrutide is not approved for routine public use.

What is Retatrutide?

Retatrutide, referred to during development as LY3437943, is an investigational peptide molecule developed as an agonist of three hormone receptor systems:

  • GIP receptor – GIPR,
  • GLP-1 receptor – GLP-1R,
  • glucagon receptor – GCGR.

It is precisely the combination of these three receptor activities in one molecule that distinguishes retatrutide from agonists targeting only one or two receptor systems.

The development designation LY3437943 is therefore frequently found in scientific publications and clinical study registries together with the name retatrutide.

Official overview:

Eli Lilly – What to know about retatrutide

Why is Retatrutide referred to as a triple receptor agonist?

The concept triple receptor agonist It describes the receptor pharmacology of the molecule. This means that retatrutide can experimentally activate three different receptors.

Receptor Abbreviations Research context
Glucose-dependent insulinotropic polypeptide receptor GIPR Incretin and metabolic signaling.
Glucagon-like peptide-1 receptor GLP-1R Incretin, neuroendocrine and metabolic signaling.
Glucagon receptor GCGR Glucagon and hepatic metabolic signaling.
Retatrutide LY3437943 Experimental integration of all three receptor systems.

The term „GLP-3“ is sometimes used in the media. However, this is not the scientific name of the new hormone class. It is only an informal name for the triple receptor agonist.

GIP receptor – GIPR

GIPR G-protein receptor is activated by the natural hormone GIP. It belongs to a group of receptors involved in incretin signaling.

In retatrutide, GIPR is studied as one of the three receptor components of a common pharmacological profile. However, it is necessary to evaluate the resulting molecule mechanistically as an integrated system and not as a simple sum of three separate agonists.

GLP-1 receptor – GLP-1R

GLP-1R It is another G protein receptor and is among the most intensively studied incretin receptors.

Retatrutide activates GLP-1R along with GIPR and GCGR. It is the current receptor activity that is the subject of pharmacological research and distinguishes this molecule from selective GLP-1 receptor agonists.

Glucagon receptor – GCGR

GCGR It is a receptor for the natural hormone glucagon. It is significantly present, for example, in liver tissue and participates in the regulation of several metabolic processes.

The incorporation of agonist activity on GCGR into a single molecule together with GIPR and GLP-1R is among the characteristic pharmacological properties of retatrutide.

Important interpretative note:

The activation of a specific receptor is a mechanistic pharmacological property. In itself, it does not demonstrate the health benefit or safety of standalone research-grade material.

Integrated receptor signaling

The most interesting scientific question regarding retatrutide is not only the activation of individual receptors, but also their interaction with each other. Combined signaling in a single molecule.

The resulting biological response may depend on:

  • the relative activity of the molecule on individual receptors,
  • expression of receptors in a specific experimental tissue,
  • concentration of the experimental substance,
  • duration of receptor exposure,
  • and a physiological or experimental model.

Therefore, it is not accurate to describe retatrutide solely as „stronger GLP-1“. This is a separate experimental receptor profile.

Phase 2 and first extensive clinical data

A significant milestone was the randomized, double-blind Phase 2 study published in 2023 New England Journal of Medicine.

The study examined adults with obesity or overweight with another defined risk factor and compared multiple dose groups of investigational retatrutide with placebo.

The authors primarily evaluated changes in body weight, safety parameters, and adverse events during the controlled clinical protocol.

Primary source:

Jastreboff et al. – Retatrutide, a triple-hormone receptor agonist for obesity – a Phase 2 trial

This is clinical research of an investigational drug produced and controlled for a specific clinical study. The results of this work cannot be used as evidence of the properties of a standalone research-grade product.

Phase 3 in 2026

As of August 2026, the clinical development of retatrutide is already in Phase 3 and includes several program studies. TRIUMPH a TRANSCEND-T2D.

One of the important changes compared to previous reviews is that the first phase 3 has already been published in a peer-reviewed journal.

TRANSCEND-T2D-1

The randomized, double-blind phase 3 TRANSCEND-T2D-1 study examined retatrutide in adults with type 2 diabetes and insufficient glycemic control with dietary and lifestyle interventions.

The results were published in a journal in 2026. The Lancet.

Bajaj et al. – TRANSCEND-T2D-1, phase 3 trial

TRIUMPH-1

TRIUMPH-1 is a Phase 3 trial in participants with obesity or overweight without type 2 diabetes. The ClinicalTrials.gov registry lists it as completed, involving more than 2,000 participants.

ClinicalTrials.gov – TRIUMPH-1, NCT05929066

TRIUMPH-2 and TRIUMPH-3

The other 3 phases study populations with type 2 diabetes and obesity or overweight, and separately a population with severe obesity and established cardiovascular disease.

ClinicalTrials.gov – TRIUMPH-2, NCT05929079

ClinicalTrials.gov – TRIUMPH-3, NCT05882045

In 2026, Lilly published the results of several Phase 3 studies. However, when conducting a scientific evaluation, it is appropriate to distinguish between: with a corporate heat-related announcement, conference presentation and a full-fledged reviewed publication.

Research program Status / data type until August 2026 Interpretation
Phase 2 – NEJM Reviewed clinical publication Controlled clinical data for the investigational product.
TRANSCEND-T2D-1 Phase 3, published in The Lancet The reviewed data of a specific clinical population.
TRIUMPH-1 Phase 3 completed; program results published It is necessary to distinguish between the register, the presented data, and the final publication.
TRIUMPH-2 / TRIUMPH-3 Phase 3; topline data published by the sponsor Not all detailed results need to be available at the same time in the reviewed publication.
TRIUMPH-Outcomes The ongoing long-term Phase 3 The results will be available only after the study is completed.

How to distinguish the level of evidence?

Retatrutide is a good example of a molecule where there are several completely different types of data.

Data type What they can show What they do not prove
Receptor experiments Activity on GIPR, GLP-1R and GCGR. The clinical outcome of a particular person.
Preclinical models Mechanisms in cellular or animal systems. Automatic efficacy or safety in humans.
Randomized clinical studies Results of an exploratory formulation in a precisely defined population. Properties of another commercially available research-grade material.
Topline results of the sponsor Preliminary summary of the main endpoints. Compensation for a complete reviewed publication.
COA research-grade batches The identity, chromatographic purity, or quantity of a specific sample according to the method used. Clinical safety or therapeutic efficacy.

Is Retatrutide an approved drug?

Retatrutide remains available until August 2026 investigative molecule. Eli Lilly states that it has not yet been approved by regulatory authorities for routine public use and its safety and efficacy continue to be evaluated in clinical development.

At the same time, the company announced in 2026 its intention to submit a regulatory application in 2027.

Current official source:

Eli Lilly – current state of development of retatrutide

Important distinction:

The clinical investigational product used in Eli Lilly studies cannot be automatically considered to be identical to research-grade material sold by an independent laboratory supplier. The same molecular name does not demonstrate a match in formulation, purity, quantity, production, or quality parameters.

Retatrutide of research grade and analytical documentation

For the laboratory customer, it is necessary to separate the clinical literature from the analytical evaluation of a specific research-grade batch.

The relevant parameters of a specific laboratory sample include:

  • molecular identity,
  • chromatographic profile,
  • HPLC area purity,
  • quantitative determination of the content,
  • batch number or lot number,
  • the used reference substance,
  • the analytical method used,
  • and the traceability of the COA to a specific batch.
Analytical note: HPLC area purity is not identical to the amount of retatrutide in the vial. Mass spectrometry can help identify the molecular signal, but by itself it does not replace the quantitative determination of the content. Each analytical result should be interpreted according to the specific method and specific batch.

More about batch evaluation, COA and analytical documentation can be found in the article 7 criteria for selecting a peptide supplier.

Available analytical documents can also be verified in the section COA and analytical documentation.

Storage of laboratory materials

Keep research-grade material at –20 °C or 2–8 °C according to the label and the CoA of the specific batch. In the case of a specific sample, the batch-specific conditions specified in the technical documentation and on the product label always take precedence.

What does the available research not show?

Despite extensive clinical development, it is necessary to rigorously separate data on investigational drug from marketing research-grade material.

The available data by themselves do not show:

  • that the research-grade sample is the same material as the investigational product of Eli Lilly,
  • clinical safety of a standalone commercial research-grade material,
  • that the results of one dose or clinical group can be extrapolated to other experimental material,
  • that receptor activity automatically means a specific health benefit,
  • that the sponsor's result of the heat is identical to the complete peer-reviewed publication,
  • that high chromatographic purity constitutes evidence of clinical efficacy,
  • that the very name „retatrutide“ confirms the origin, manufacturer, or pharmaceutical equivalence of a specific sample.

Therefore, for a research-grade informational or product page, it is not appropriate to use consumer-oriented terms such as „revolutionary drug“, „weight loss peptide“, „strongest fat burner“, „Ozempic replacement“, or other claims aimed at personal health outcomes.

How to critically read studies on Retatrutide?

It is advisable to verify with each source:

  • whether it is receptor-based, preclinical or clinical research,
  • the phase of a clinical study,
  • the studied population,
  • primary and secondary endpoints,
  • whether the results are just heat or already reviewed,
  • whether the publication is a primary work or a secondary review,
  • and whether it is an investigative product from the sponsor of the clinical study or independent research-grade material.

FAQ – Retatrutide research

What is Retatrutide?

Retatrutide, developed as LY3437943, is an investigational molecule with agonist activity on the GIPR, GLP-1R and GCGR receptors.

What does a triple receptor agonist mean?

This means that one molecule activates three receptor systems – GIP, GLP-1 and the glucagon receptor. This is a pharmacological description of the receptor profile.

Is Retatrutide GLP-3?

No. „GLP-3“ is an informal media term and is not a scientific hormonal classification. Retatrutide is more accurately referred to as an agonist of GIPR, GLP-1R and GCGR.

Are there Phase 3 studies?

Yes. As of August 2026, a large Phase 3 program, TRANSCEND-T2D-1, has already been published in a peer-reviewed journal, and further studies of the TRIUMPH program are complete or ongoing.

Is Retatrutide approved for regular use?

No. Until August 2026, it remains an investigational molecule and clinical development continues.

Is the research-grade Retatrutide the same as the product used in clinical studies?

Such equivalence cannot be assumed. The same molecular name does not confirm the same manufacturer, formulation, batch, purity, quantity, or pharmaceutical quality.

What does HPLC purity mean?

HPLC area purity describes the relative representation of chromatographic signals within a specific analytical method. It is not identical to the amount of material in the vial and does not represent evidence of clinical safety or efficacy.

How is research-grade Retatrutide stored?

According to the label and CoA of the specific batch, typically when –20 °C or 2–8 °C, If the technical documentation of a specific product states so.

You can find more professional articles in the section Research on peptides.

Scientific and official sources

  1. Jastreboff AM, Kaplan LM, Frías JP, et al.
    Retatrutide, an agonist of the triple-receptor for obesity – a Phase 2 trial.
    New England Journal of Medicine. 2023.
    PubMed
  2. Bajaj HS, Welch M, Shah P, et al.
    Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycemic control with diet and exercise – TRANSCEND-T2D-1.
    The Lancet. 2026.
    PubMed
  3. Giblin K, Kaplan LM, Somers VK, et al.
    Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: rationale and design of the TRIUMPH registrational clinical trials.
    Diabetes, Obesity and Metabolism. 2026.
    PubMed
  4. ClinicalTrials.gov.
    TRIUMPH-1 – NCT05929066.
    ClinicalTrials.gov
  5. ClinicalTrials.gov.
    TRIUMPH-2 – NCT05929079.
    ClinicalTrials.gov
  6. ClinicalTrials.gov.
    TRIUMPH-3 – NCT05882045.
    ClinicalTrials.gov
  7. ClinicalTrials.gov.
    TRIUMPH-Outcomes – NCT06383390.
    ClinicalTrials.gov
  8. Eli Lilly and Company.
    What to know about retatrutide.
    Eli Lilly
Important notice:

This article is for informational, educational, and scientific purposes only. The information describes receptor, molecular, preclinical, and clinical research data and does not constitute medical advice, diagnosis, prevention, or treatment instructions.

The results of clinical studies with investigational retatrutide cannot be automatically transferred to standalone research-grade material from another manufacturer or supplier. The same molecular name does not indicate pharmaceutical equivalence.

Retatrutide of research grade and other materials presented on the NEXXUS BIO website are intended solely for laboratory, analytical and scientific purposes (Research Use Only). They are not intended for human or veterinary use, consumption, personal application, diagnosis, prevention or treatment.

8%

Zľava na váš ďalší nákup🎁

Prihláste sa na odber noviniek NexxusBio a získajte 8 % zľavu. Po potvrdení prihlásenia vám pošleme zľavový kód e-mailom.

Nespamujeme! Pre viac informácií si prečítajte naše zásady ochrany osobných údajov. Z odberu sa môžete kedykoľvek odhlásiť. Zľava sa nekombinuje s inými zľavovými kódmi.